IP Library Granted Patent US 9,926,337
Granted Patent B2
US 9,926,337 · App. 15/368,362 · Granted Mar 27, 2018

Substituted asymmetric ureas as modulators of ghrelin receptor activity

Inventors: Claudio Giuliano (Como, IT); Silvina Garcia Rubio (Princeton, NJ); Antoine Daina (Lausanne, CH); Angelo Guainazzi (Iselin, NJ); Claudio Pietra (Como, IT)
Assignee: HELSINN HEALTHCARE SA
C07F7/0812C07D211/58C07D211/60C07D211/94C07D211/96C07D213/00C07D239/26C07D241/12C07D401/06C07D401/12C07D401/14C07D403/12C07D405/12C07D405/14C07D409/12C07D409/14C07D413/12C07D417/12C07D417/14C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,926,337
App. No.
15/368,362
Granted
Mar 27, 2018
Kind
B2
Abstract

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.

Claims (296)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

is a single bond;

X is CH or N;

Z is NR 9 ;

R 1 is H, OH, C 1-6 alkyl, benzyl, or C 1-6 alkoxy, wherein the C 1-6 alkyl, benzyl, or C 1-6 alkoxy is optionally substituted with 1-3 substituents selected from halo, OH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, CO(C 1-6 alkyl), CHO, CO 2 H, CO 2 (C 1-6 alkyl), and C 1-6 haloalkyl;

R 2 is H or C 1-6 alkyl;

R 3 and R 4 are each independently H, CN, halo, CHO, CO 2 H, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 alkylcycloalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, CO(C 1-6 alkyl), CO 2 (C 1-6 alkyl), or CONR 12 R 13 ;

or R 3 and R 4 taken together with the carbon atom to which they are attached form a 3-6-membered ring;

R 5 is halo, CN, CHO, CO 2 H, CO(C 1-6 alkyl), CO 2 (C 1-6 alkyl), NR 14 R 15 , NHCONR 14 R 15 , CONR 14 R 15 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein the CO(C 1-6 alkyl), CO 2 (C 1-6 alkyl), NR 14 R 15 , NHCONR 14 R 15 , CONR 14 R 15 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1-3 substituents selected from halo, CN, OH, NO 2 , Si(CH 3 ) 3 , CHO, and CO 2 H;

R 6 is H;

R 7 is H, CN, or halo;

R 8 is H or C 1-6 alkyl;

R 9 is H, C 1-6 alkyl, CO(C 1-6 alkyl), CHO, CO 2 H, or CO 2 (C 1-6 alkyl);

R 12 and R 13 are each independently H or C 1-6 alkyl;

R 14 and R 15 are each independently H, C 1-6 alkyl, CO(C 1-6 alkyl), CO(heteroaryl), heteroaryl, or cycloalkyl;

r is 1;

s is 0, 1, 2, 3 or 4; and

n is 0, 1, 2, or 3.

2. The compound of claim 1 , wherein R 1 is C 1-6 alkyl.

3. The compound of claim 1 , wherein R 1 is benzyl.

4. The compound of claim 1 , wherein R 1 is OH.

5. The compound of claim 1 , wherein R 1 is C 1-6 alkoxy.

6. The compound of claim 1 , wherein R 2 is H.

7. The compound of claim 1 , wherein R 3 and R 4 are each independently C 1-6 alkyl, CN, C 1-6 alkylcycloalkyl, C 1-6 hydroxyalkyl, CO 2 (C 1-6 alkyl), C 1-6 haloalkyl, or CONH 2 .

8. The compound of claim 1 , wherein R 3 and R 4 taken together with the carbon atom to which they are attached form a 3-6-membered ring.

9. The compound of claim 1 , wherein R 5 is C 1-6 haloalkyl, heteroaryl, aryl, halo, C 1-6 alkoxy, CO 2 (C 1-6 alkyl), C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, or heterocycloalkyl.

10. The compound of claim 1 , wherein R 7 is halo.

11. The compound of claim 1 , wherein R 8 is H.

12. The compound of claim 1 , wherein R 8 is C 1-6 alkyl.

13. The compound of claim 1 , wherein R 8 is CH 3 .

14. The compound of claim 1 , wherein X is CH.

15. The compound of claim 1 , wherein X is N.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , and one or more pharmaceutically acceptable excipients.

17. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

is a single bond;

X is CH or N;

Z is NR 9 ;

R 1 is H, OH, C 1-6 alkyl, benzyl, or C 1-6 alkoxy, wherein the C 1-6 alkyl, benzyl, or C 1-6 alkoxy is optionally substituted with 1-3 substituents selected from halo, OH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, CO(C 1-6 alkyl), CHO, CO 2 H, CO 2 (C 1-6 alkyl), and C 1-6 haloalkyl;

R 2 is H or C 1-6 alkyl;

R 3 and R 4 are each independently H, CN, halo, CHO, CO 2 H, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 alkylcycloalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, CO(C 1-6 alkyl), CO 2 (C 1-6 alkyl), or CONR 12 R 13 ;

or R 3 and R 4 taken together with the carbon atom to which they are attached form a 3-6-membered ring;

R 5 is C 2-6 alkynyl, optionally substituted with 1-3 substituents selected from halo, CN, OH, NO 2 , Si(CH 3 ) 3 , CHO, CO 2 H, CO(C 1-6 alkyl), CO 2 (C 1-6 alkyl), NR 14 R 15 , NHCONR 14 R 15 , CONR 14 R 15 , CH═NOH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl;

R 6 is H;

R 7 is H, CN, or halo;

R 8 is H or C 1-6 alkyl;

R 9 is H, C 1-6 alkyl, CO(C 1-6 alkyl), CHO, CO 2 H, or CO 2 (C 1-6 alkyl);

R 12 and R 13 are each independently H or C 1-6 alkyl;

R 14 and R 15 are each independently H, C 1-6 alkyl, CO(C 1-6 alkyl), CO(heteroaryl), heteroaryl, or cycloalkyl;

r is 2;

s is 0, 1, 2, 3, or 4; and

n is 0, 1, 2, or 3.

18. A compound of Formula II:

or a pharmaceutically acceptable salt thereof, wherein:

is a single bond;

X is CH or N;

Z is NR 9 ;

R 1 is H, OH, C 1-6 alkyl, benzyl, or C 1-6 alkoxy, wherein the C 1-6 alkyl, benzyl, or C 1-6 alkoxy is optionally substituted with 1-3 substituents selected from halo, OH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, CO(C 1-6 alkyl), CHO, CO 2 H, CO 2 (C 1-6 alkyl), and C 1-6 haloalkyl;

R 2 is H or C 1-6 alkyl;

R 3 and R 4 are each independently H, CN, halo, CHO, CO 2 H, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 alkylcycloalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, CO(C 1-6 alkyl), CO 2 (C 1-6 alkyl), or CONR 12 R 13 ;

or R 3 and R 4 taken together with the carbon atom to which they are attached form a 3-6-membered ring;

R 5 is C 2-6 alkynyl or heteroaryl, wherein the C 2-6 alkynyl or heteroaryl is optionally substituted with 1-3 substituents selected from halo, CN, OH, NO 2 , Si(CH 3 ) 3 , CHO, CO 2 H, CO(C 1-6 alkyl), CO 2 (C 1-6 alkyl), NR 14 R 15 , NHCONR 14 R 15 , CONR 14 R 15 , CH═NOH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl;

R 6 is H;

each R 7 is independently halo;

R 8 is H or C 1-6 alkyl;

R 9 is H, C 1-6 alkyl, CO(C 1-6 alkyl), CHO, CO 2 H, or CO 2 (C 1-6 alkyl);

R 12 and R 13 are each independently H or C 1-6 alkyl;

R 14 and R 15 are each independently H, C 1-6 alkyl, CO(C 1-6 alkyl), CO(heteroaryl), heteroaryl, or cycloalkyl;

r is 2;

s is 0, 1, 2, 3, or 4; and

n is 0, 1, 2, or 3.

19. A compound selected from the group consisting of:

Compound

No.

Chemical Structure

Chemical Name

H0494

3-(1-(2,3-dichloro-4- cyclopropylphenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0621

3-(1-(2,3-dichloro-4- (difluoromethyl)phenyl)ethyl)-1-hydroxy- 1-(1-methylpiperidin-4-yl)urea

H0526

3-(1-(2,3-dichloro-4-(pyridin-3- yl)phenyl)ethyl)-1-methyl-1-(1- methylpyrrolidin-3-yl)urea

H0578

1-methyl-1-(1-methylpiperidin-4-yl)-3-(1- (4-(pyridin-4-yl)naphthalen-1- yl)ethyl)urea

H0579

1-methyl-1-(1-methylpiperidin-4-yl)-3-(1- (4-(pyrimidin-5-yl)naphthalen-1- yl)ethyl)urea

H0584

1-cyclohexyl-3-(1-(2,3-dichloro-4- (pyrimidin-5-yl)phenyl)ethyl)-1- methylurea

H0586

3-(1-(2,3-dichloro-4-(pyrimidin-5- yl)phenyl)ethyl)-1-methyl-1-(tetrahydro- 2H-pyran-4-yl)urea

H0587

3-(1-(2,3-dichloro-4-(pyrimidin-5- yl)phenyl)ethyl)-1-(4,4- difluorocyclohexyl)-1-methylurea

H0837

3-((S)-1-(2,3-dichloro-4-(pyrazin-2- yl)phenyl)ethyl)-1-methyl-1-(1- methylpyrrolidin-3-yl)urea (diasteromeric mixture)

H0861

3-((S)-1-(2,3-dichloro-4-(pyrazin-2- yl)phenyl)ethyl)-1-methyl-1-(1- methylpyrrolidin-3-yl)urea (single diastereoisomer)

H0862

3-((S)-1-(2,3-dichloro-4-(pyrazin-2- yl)phenyl)ethyl)-1-methyl-1-(1- methylpyrrolidin-3-yl)urea (single diastereoisomer)

H0857

3-(1-(2,3-dichloro-4-(pyrazin-2- yl)phenyl)propyl)-1-methyl-1-(1- methylpyrrolidin-3-yl)urea

H0871

3-(1-(2,3-dichloro-4-(pyrazin-2- yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl- 1-(1-methylpyrrolidin-3-yl)urea

H0874

3-(2-cyclopropyl-1-(2,3-dichloro-4- (pyrazin-2-yl)phenyl)ethyl)-1-methyl-1- (1-methylpyrrolidin-3-yl)urea

H0853

N-(1-(2,3-dichloro-4-(pyrazin-2- yl)phenyl)ethyl)-2-(4-methylpiperazin-1- yl)propanamide

H0864

3-(1-(2,3-dichloro-4-(6-fluoropyrazin-2- yl)phenyl)propyl)-1-methyl-1-(1- methylpyrrolidin-3-yl)urea

H0872

3-((S)-1-(2,3-dichloro-4-(6-fluoropyrazin- 2-yl)phenyl)ethyl)-1-methyl-1-(1- methylpyrrolidin-3-yl)urea

H0850

1-methyl-1-(1-methylpiperidin-4-yl)-3-(1- (4-(pyrazin-2-yl)naphthalen-1- yl)ethyl)urea

H0531

3-(1-(2,3-dichloro-4-(thiophen-3- yl)phenyl)ethyl)-1-methyl-1-(1- methylpyrrolidin-3-yl)urea

H0529

3-(1-(2,3-dichloro-4-(1H-pyrazol-4- yl)phenyl)ethyl)-1-methyl-1-(1- methylpyrrolidin-3-yl)urea

H0508

3-(1-(2,3-dichloro-4′-methoxy-[1,1′- biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0509

3-(1-(2,3-dichloro-[1,1′-biphenyl]-4- yl)ethyl)-1-methyl-1-(1-methylpiperidin- 4-yl)urea

H0510

3-(1-(3′-amino-2,3-dichloro-[1,1′- biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0606

3-(1-(2,3-dichloro-3′-methoxy-[1,1′- biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0810

3-(1-(2,3-dichloro-3′-fluoro-[1,1′- biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0696

3-(1-(2,3-dichloro-3′-fluoro-5′- (hydroxymethyl)-[1,1′-biphenyl]-4- yl)ethyl)-1-methyl-1-(1-methylpiperidin- 4-yl)urea

H0611

3-(1-(2,3-dichloro-3′,5′-dimethoxy-[1,1′- biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0612

2′,3′-dichloro-4′-(1-(3-methyl-3-(1- methylpiperidin-4-yl)ureido)ethyl)-[1,1′- biphenyl]-3-carboxamide

H0615

2′,3′-dichloro-4′-(1-(3-methyl-3-(1- methylpiperidin-4-yl)ureido)ethyl)-[1,1′- biphenyl]-4-carboxamide

H0809

3-(1-(2,3-dichloro-4′-cyano-[1,1′- biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0610

3-(1-(2,3-dichloro-3′-cyano-[1,1′- biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0517

3-(1-(4′-amino-2,3-dichloro-[1,1′- biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0518

3-(1-(2,3-dichloro-4′-(dimethylamino)- [1,1′-biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0520

3-(1-(2,3-dichloro-2′,3′,4′,5′-tetrahydro- [1,1′-biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0787

3-(1-(3- (cyclopropylamino)benzo[d]isoxazol-6- yl)ethyl)-1-methyl-1-(1-methylpiperidin- 4-yl)urea

H0605

3-(1-(2,3-dichloro-3′,5′-difluoro-[1,1′- biphenyl]-4-yl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0573

3-(1-(4-bromonaphthalen-1-yl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea

H0574

1-methyl-1-(1-methylpiperidin-4-yl)-3-(1- (4-(thiophen-3-yl)naphthalen-1- yl)ethyl)urea

H0575

1-methyl-1-(1-methylpiperidin-4-yl)-3-(1- (4-(thiophen-2-yl)naphthalen-1- yl)ethyl)urea

H0576

3-(1-(4-(1H-pyrazol-4-yl)naphthalen-1- yl)ethyl)-1-methyl-1-(1-methylpiperidin- 4-yl)urea

H0577

1-methyl-1-(1-methylpiperidin-4-yl)-3-(1- (4-(pyridin-3-yl)naphthalen-1- yl)ethyl)urea

H0591

3-(1-(4-(3-aminophenyl)naphthalen-1- yl)ethyl)-1-methyl-1-(1-methylpiperidin- 4-yl)urea

H0597

1-methyl-1-(1-methylpiperidin-4-yl)-3-(1- (4-(thiazol-5-yl)naphthalen-1- yl)ethyl)urea

H0598

3-(1-(4-(furan-3-yl)naphthalen-1- yl)ethyl)-1-methyl-1-(1-methylpiperidin- 4-yl)urea

H0599

3-(1-(4-(1H-imidazol-5-yl)naphthalen-1- yl)ethyl)-1-methyl-1-(1-methylpiperidin- 4-yl)urea

H0790

3-(1-(4-cyanonaphthalen-1-yl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea

H0519

3-(1-(2,3-dichloro-4-iodophenyl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea

H0629

3-((3-bromo-2-chloro-4- iodophenyl)(cyano)methyl)-1-methyl-1- (1-methylpiperidin-4-yl)urea

H0658

3-((3-bromo-2-chloro-4- methoxyphenyl)(cyano)methyl)-1-methyl- 1-(1-methylpiperidin-4-yl)urea

H0669

3-(cyano(2,3-dichloro-4- methoxyphenyl)methyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0671

3-(1-cyano-1-(2,3-dichloro-4- methoxyphenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0659

2-(3-bromo-2-chloro-4-methoxyphenyl)- 2-(3-methyl-3-(1-methylpiperidin-4- yl)ureido)acetamide

H0521

methyl 2,3-dichloro-4-(1-(3-methyl-3-(1- methylpiperidin-4- yl)ureido)ethyl)benzoate

H0602

3-(1-(2,3-dichloro-4- ((trimethylsilyl)ethynyl)phenyl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea

H0603

3-(1-(2,3-dichloro-4- ethynylphenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0677

3-(1-(2,3-dichloro-4- ethynylphenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea (single enantiomer)

H0678

3-(1-(2,3-dichloro-4- ethynylphenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea (single enantiomer)

H0832

3-(1-(2,3-dichloro-4-(prop-1-yn-1- yl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0852

3-(1-(2,3-dichloro-4-(3-methylbut-1-yn-1- yl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0701

3-(1-(2,3-dichloro-4-(3-oxobut-1-yn-1- yl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0733

3-(1-(2,3-dichloro-4-(3-hydroxybut-1-yn- 1-yl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0755

3-(1-(2,3-dichloro-4-(3-hydroxyprop-1- yn-1-yl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0757

3-(1-(2,3-dichloro-4-(3,3-diethoxyprop-1- yn-1-yl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0734

3-(1-(2,3-dichloro-4-(pyridin-2- ylethynyl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0737

3-(1-(2,3-dichloro-4-(thiophen-2- ylethynyl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0775

3-(1-(2,3-dichloro-4-((5- (hydroxymethyl)thiophen-2- yl)ethynyl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0776

5-((2,3-dichloro-4-(1-(3-methyl-3-(1- methylpiperidin-4- yl)ureido)ethyl)phenyl)ethynyl)thiophene- 2-carboxamide

H0779

methyl 5-((2,3-dichloro-4-(1-(3-methyl-3- (1-methylpiperidin-4- yl)ureido)ethyl)phenyl)ethynyl)thiophene- 2-carboxylate

H0762

3-(1-(2,3-dichloro-4-(furan-2- ylethynyl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0751

3-(1-(2,3-dichloro-4-(thiazol-4- ylethynyl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0763

3-(1-(4-((1H-imidazol-4-yl)ethynyl)-2,3- dichlorophenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0759

3-(1-(2,3-dichloro-4-(thiophen-3- ylethynyl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0785

3-(1-(2,3-dichloro-4-(3-(thiophen-2- yl)prop-1-yn-1-yl)phenyl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea

H0754

3-(1-(2,3-dichloro-4-(thiazol-2- ylethynyl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0753

3-(1-(2,3-dichloro-4-(pyrimidin-5- ylethynyl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0609

3-(1-(2,3-dichloro-4- (phenylethynyl)phenyl)ethyl)-1-methyl-1- (1-methylpiperidin-4-yl)urea

H0764

3-(1-(2,3-dichloro-4- (cyclopropylethynyl)phenyl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea

H0818

3-(1-(2,3-dichloro-4- (cyclopropylethynyl)phenyl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea (single enantiomer)

H0819

3-(1-(2,3-dichloro-4- (cyclopropylethynyl)phenyl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea (single enantiomer)

H0838

3-((S)-1-(2,3-dichloro-4- (cyclopropylethynyl)phenyl)ethyl)-1- methyl-1-(1-methylpyrrolidin-3-yl)urea

H0855

3-(1-(3-chloro-4-(cyclopropylethynyl)-2- fluorophenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0884

3-(1-(4,5-dichloro-6- (cyclopropylethynyl)pyridin-3-yl)ethyl)- 1-methyl-1-(1-methylpiperidin-4-yl)urea

H0811

3-(1-(2,3-dichloro-4- (cyclopentylethynyl)phenyl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea

H0812

3-(1-(2,3-dichloro-4-(3-(4- methylpiperazin-1-yl)prop-1-yn-1- yl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0740

3-(2-cyclopropyl-1-(2,3-dichloro-4- ethynylphenyl)ethyl)-1-methoxy-1-(1- methylpiperidin-4-yl)urea

H0742

3-(1-(2,3-dichloro-4- ethynylphenyl)ethyl)-1-methoxy-1-(1- methylpiperidin-4-yl)urea

H0745

3-(1-(2,3-dichloro-4- ethynylphenyl)ethyl)-1-hydroxy-1-(1- methylpiperidin-4-yl)urea

H0749

3-(1-(2,3-dichloro-4- ethynylphenyl)ethyl)-1-ethoxy-1-(1- methylpiperidin-4-yl)urea

H0744

3-(2-cyclopropyl-1-(2,3-dichloro-4- ethynylphenyl)ethyl)-1-ethoxy-1-(1- methylpiperidin-4-yl)urea

H0626

3-(1-(2,3-dichloro-4-vinylphenyl)ethyl)- 1-methyl-1-(1-methylpiperidin-4-yl)urea

H0767

(E)-3-(1-(2,3-dichloro-4-(2-(thiophen-2- yl)vinyl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0772

N-(2,3-dichloro-4-(1-(3-methyl-3-(1- methylpiperidin-4- yl)ureido)ethyl)phenyl)thiophene-2- carboxamide

H0773

2,3-dichloro-4-(1-(3-methyl-3-(1- methylpiperidin-4-yl)ureido)ethyl)-N- (thiophen-2-yl)benzamide

H0784

3-(1-(2,3-dichloro-4-(3-(thiophen-2- yl)ureido)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0777

3-(1-(2,3-dichloro-4-(thiophen-2- ylamino)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0846

3-(1-(2,3-dichloro-4- (cyclopropylamino)phenyl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea

H0875

3-(1-(2,3-dichloro-4- cyclopropoxyphenyl)ethyl)-1-methyl-1- (1-methylpiperidin-4-yl)urea

H0628

3-(1-(2,3-dichloro-4-ethylphenyl)ethyl)-1- methyl-1-(1-methylpiperidin-4-yl)urea

H0630

3-(1-(2,3-dichloro-4- (cyanomethyl)phenyl)ethyl)-1-methyl-1- (1-methylpiperidin-4-yl)urea

H0633

3-(1-(2,3-dichloro-4- (hydroxymethyl)phenyl)ethyl)-1-methyl- 1-(1-methylpiperidin-4-yl)urea

H0634

3-(1-(2,3-dichloro-4- (fluoromethyl)phenyl)ethyl)-1-methyl-1- (1-methylpiperidin-4-yl)urea

H0640

3-(1-(2,3-dichloro-4-formylphenyl)ethyl)- 1-methyl-1-(1-methylpiperidin-4-yl)urea

H0645

3-(1-(2,3-dichloro-4-(1,3-dioxolan-2- yl)phenyl)ethyl)-1-methyl-1-(1- methylpiperidin-4-yl)urea

H0641

methyl (E)-3-(2,3-dichloro-4-(1-(3- methyl-3-(1-methylpiperidin-4- yl)ureido)ethyl)phenyl)acrylate

H0702

(Z)-3-(1-(2,3-dichloro-4-(1-chloro-3- oxobut-1-en-1-yl)phenyl)ethyl)-1-methyl- 1-(1-methylpiperidin-4-yl)urea

H0643

3-(1-(2,3-dichloro-4-(3- hydroxypropyl)phenyl)ethyl)-1-methyl-1- (1-methylpiperidin-4-yl)urea

H0522

2,3-dichloro-4-(1-(3-methyl-3-(1- methylpiperidin-4- yl)ureido)ethyl)benzamide

H0523

3-(1-(2,3-dichloro-4-cyanophenyl)ethyl)- 1-methyl-1-(1-methylpiperidin-4-yl)urea

H0876

1-methyl-1-(1-methylpiperidin-4-yl)-3-(1- (4,5,6-trichloropyridin-3-yl)ethyl)urea

or a pharmaceutically acceptable salt thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2023
From: HAMILTON SA LLC
To: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 064961/0567 →
SECURITY INTEREST Recorded Dec 30, 2022
From: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
To: HAMILTON SA LLC
Reel/Frame 062254/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2016
From: GIULIANO, CLAUDIO; RUBIO, SILVINA GARCIA; DAINA, ANTOINE; GUAINAZZI, ANGELO; PIETRA, CLAUDIO
To: HELSINN HEALTHCARE SA
Reel/Frame 040531/0522 →
Continuity (3)
Division 14640551 · Mar 6, 2015
Provisional Application 61949664 · Mar 7, 2014
Related Publication 20170145038A1 · May 25, 2017